Haemonetics

US · HAE #2165 by market cap Listed 1970

101.71 -1.81 -1.75%

Live - 5344 symbols - heartbeat 509s ago · 2026-10-08 08:29

Pre-market 117.00 +15.03%

After-hours 101.71 0.00%

Market cap: 4.63B
P/E (TTM): 49.14
P/B: 5.53
EPS: 2.05
Div yield: 0.00%
52W pos: 86%

Reader sentiment Are you bullish or bearish on HAE?

Anonymous reader poll. Unscientific, not investment advice.

✦ Quant Financial Health how this is computed

Good

Altman Z-Score is 3.06, above the 3.0 "safe zone" threshold.
Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.

Revenue annual, last 8 years

Latest year -1.97% YoY

Margins

Gross margin: 59.04%
Operating margin: 18.10%
Net margin: 7.29%

Key ratios & quality

Enterprise value: 5.61B
Altman Z-Score: 3.06

Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.

Income statement

Line item	2019	2020	2021	2022	2023	2024	2025	2026
Revenue	967.58M	988.48M	870.46M	993.20M	1.17B	1.31B	1.36B	1.33B
Gross profit	417.54M	484.51M	397.84M	505.50M	615.10M	691.55M	748.96M	787.59M
Selling & admin expenses	273.47M	282.02M	275.22M	340.14M	376.68M	429.78M	436.79M	442.42M
Research & development	35.71M	30.88M	32.86M	46.80M	50.13M	54.44M	62.72M	59.77M
Operating profit	83.55M	145.87M	56.94M	71.15M	155.65M	175.30M	201.19M	241.40M
Pretax profit	73.63M	87.15M	72.91M	63.63M	141.40M	151.87M	212.07M	128.03M
Tax	18.61M	10.63M	-6.56M	20.25M	26.00M	34.31M	44.39M	30.72M
Net profit	55.02M	76.53M	79.47M	43.38M	115.40M	117.56M	167.68M	97.31M
Basic EPS	1	2	2	1	2	2	3	2
Diluted EPS	1.04	1.48	1.55	0.84	2.24	2.29	3.31	2.05

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Revenue	330.60M	321.39M	327.32M	338.97M	346.35M	339.38M
Gross profit	193.05M	192.24M	194.74M	202.39M	198.21M	202.80M
Selling & admin expenses	115.14M	110.72M	101.62M	109.15M	120.93M	118.94M
Research & development	18.31M	16.26M	14.87M	14.19M	14.45M	16.20M
Operating profit	48.31M	53.87M	67.08M	68.11M	52.34M	57.46M
Pretax profit	70.74M	45.17M	51.29M	59.98M	-28.40M	47.57M
Tax	12.76M	11.14M	12.60M	15.24M	-8.25M	14.56M
Net profit	57.98M	34.03M	38.68M	44.74M	-20.15M	33.01M
Basic EPS	1	1	1	1	0	1
Diluted EPS	1.17	0.70	0.81	0.95	-0.44	0.72

Balance sheet

Line item	2019	2020	2021	2022	2023	2024	2025	2026
Total current assets	576.12M	603.64M	693.55M	756.03M	769.72M	768.90M	934.98M	834.88M
Cash & ST investments	169.35M	137.31M	192.31M	259.50M	284.47M	178.80M	306.76M	245.44M
Inventory	194.34M	270.28M	322.61M	293.03M	259.38M	317.20M	365.14M	306.37M
Total assets	1.27B	1.27B	1.82B	1.86B	1.93B	2.20B	2.45B	2.40B
Total current liabilities	235.76M	274.82M	253.50M	442.27M	251.82M	300.38M	578.11M	282.60M
Short-term debt	27.67M	84.29M	24.72M	214.15M	11.78M	10.23M	303.56M	5.02M
Long-term debt	322.45M	305.51M	690.59M	559.44M	754.10M	797.56M	921.23M	1.22B
Total liabilities	606,899,000.00	680,001,000.00	1,088,253,000.00	1,110,310,000.00	1,116,828,000.00	1,235,632,000.00	1,630,112,000.00	1,599,605,000.00
Total equity	667.87M	587.11M	731.67M	749.42M	818.00M	959.96M	820.84M	796.32M
Retained earnings	161.42M	78.51M	157.98M	202.39M	253.17M	360.46M	352.17M	279.34M

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Total current assets	934.98M	913.16M	899.68M	943.67M	834.88M	810.83M
Cash & ST investments	306.76M	292.90M	296.43M	363.37M	245.44M	223.38M
Inventory	365.14M	360.53M	336.21M	321.19M	306.37M	306.74M
Total assets	2.45B	2.46B	2.44B	2.49B	2.40B	2.37B
Total current liabilities	578.11M	531.41M	548.32M	539.87M	282.60M	263.24M
Short-term debt	303.56M	303.95M	304.34M	304.75M	5.02M	4.96M
Long-term debt	921.23M	920.83M	920.39M	919.99M	1.22B	1.17B
Total liabilities	1,630,112,000.00	1,579,794,000.00	1,592,983,000.00	1,579,439,000.00	1,599,605,000.00	1,528,299,000.00
Total equity	820.84M	882.30M	849.17M	911.45M	796.32M	837.10M
Retained earnings	352.17M	356.05M	336.32M	381.09M	279.34M	311.52M

Cash flow

Line item	2019	2020	2021	2022	2023	2024	2025	2026
Operating cash flow	159.28M	158.22M	108.81M	172.26M	273.06M	181.75M	181.73M	293.22M
Depreciation & amortization	109.42M	110.29M	84.29M	97.75M	93.31M	97.22M	115.59M	111.72M
Free cash flow	40.32M	109.46M	71.77M	75.75M	81.73M	143.63M	142.45M	260.44M
Dividends paid	--	--	--	--	--	--	--	--
Stock buybacks / issuance	-160.00M	-175.00M	0	0	-75.00M	0	-225.00M	-175.00M
Ending cash balance	169.35M	137.31M	192.31M	259.50M	284.47M	178.80M	306.76M	245.44M

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Operating cash flow	116.56M	17.40M	111.32M	93.56M	70.94M	52.32M
Depreciation & amortization	28.21M	28.76M	28.26M	27.39M	27.32M	27.11M
Free cash flow	100.91M	13.64M	106.31M	87.22M	53.28M	44.42M
Dividends paid	--	--	--	--	--	--
Stock buybacks / issuance	-150.00M	--	--	0	-100.00M	--
Ending cash balance	306.76M	292.90M	296.43M	363.37M	245.44M	223.38M

Returns & efficiency

Line item	2019	2020	2021	2022	2023	2024	2025	2026
ROE %	7.75	12.20	12.05	5.86	14.73	13.22	18.83	12.03
ROA %	4.38	6.02	5.15	2.36	6.08	5.69	7.22	4.02
ROIC %	6.17	8.87	7.23	3.62	8.18	7.62	9.20	5.86
5-year avg ROE %	1.02	3.05	6.90	8.79	10.52	11.61	12.94	12.93
EBIT margin %	8.63	10.46	10.31	8.13	13.35	12.60	16.30	11.75
FCF / sales %	4.17	11.07	8.24	7.63	13.94	8.82	10.47	19.52
Current ratio	2.44	2.20	2.74	1.71	3.06	2.56	1.62	2.95
Quick ratio	1.50	1.10	1.26	0.95	1.84	1.28	0.88	1.64
Debt / assets	27.47	34.87	39.30	41.60	39.58	36.79	49.97	51.11
LT debt / equity	48.28	60.90	94.39	74.65	92.19	83.08	112.23	153.15
Interest coverage	8.43	6.38	5.33	4.72	10.67	12.67	22.76	5.46
Revenue CAGR (3Y) %	2.11	3.71	-1.25	0.87	5.74	14.57	11.07	4.51
Net income CAGR (3Y) %	--	--	20.36	-7.62	14.67	13.94	56.94	-5.53
FCF CAGR (3Y) %	27.49	9.40	-21.00	23.39	-9.28	26.02	23.43	47.15

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
ROE %	18.83	18.27	19.47	19.30	12.03	11.20
ROA %	7.22	6.53	6.77	6.99	4.02	3.99
ROIC %	9.20	7.71	9.00	9.09	5.86	5.75
5-year avg ROE %	--	--	--	--	--	--
EBIT margin %	16.30	17.53	18.28	19.05	11.75	11.86
FCF / sales %	10.47	14.05	19.29	23.37	19.52	21.54
Current ratio	1.62	1.72	1.64	1.75	2.95	3.08
Quick ratio	0.88	0.93	0.92	1.04	1.64	1.67
Debt / assets	49.97	49.75	50.15	49.17	51.11	49.64
LT debt / equity	112.23	104.37	108.39	100.94	153.15	139.67
Interest coverage	22.76	--	9.47	10.49	5.46	5.36
Revenue CAGR (3Y) %	--	--	--	--	--	--
Net income CAGR (3Y) %	--	--	--	--	--	--
FCF CAGR (3Y) %	--	--	--	--	--	--

✦ Quant Revenue Concentration how this is computed

Lead segment, long tail

Apheresis is the largest reported line at 56.37% of revenue, across 2 reported segments.
MedSurg follows at 43.63%, so the top line still matters most but isn’t the whole story.

Revenue breakdown most recent period

Business

Apheresis56.37%

MedSurg43.63%

Quote time 2026-10-08 08:29:55 · For reference only, not investment advice and not tailored to your situation.